Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 5/20 | 0.51 |
| ▸ | HTR6 | P50406 | 9/20 | 0.43 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014306 | 0.90 | HTR6 (0.46) | SFRP1HTR6 | |
| SCHEMBL1015216 | 0.90 | HTR6 (0.46) | SFRP1HTR6 | |
| SCHEMBL1015637 | 0.86 | SFRP1 (0.41) | SFRP1HTR6XIAPBIRC2 | |
| SCHEMBL1016616 | 0.85 | HTR6 (0.53) | SFRP1HTR6 | |
| SCHEMBL1015497 | 0.82 | HTR6 (0.45) | SFRP1HTR6DRD3DRD2 | |
| SCHEMBL1013368 | 0.80 | HTR6 (0.43) | HTR6DRD3 | |
| SCHEMBL1012565 | 0.79 | HTR6 (0.47) | SFRP1HTR6 | |
| SCHEMBL1015805 | 0.77 | HTR6 (0.48) | HTR6 | |
| SCHEMBL1015804 | 0.77 | HTR6 (0.48) | HTR6 | |
| SCHEMBL1016516 | 0.76 | HTR6 (0.50) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | SFRP1 3537/4885HTR6 1/4885XIAP 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.